Profile
Guy Debruyne is currently a Director at Le Bocholtz SA, Mithra Pharmaceuticals CDMO SA, Blue Star Invest SA, and a Director at CG Cube SA. He was previously a Non-Executive Director at Mithra Pharmaceuticals SA.
Guy Debruyne active positions
Companies | Position | Start |
---|---|---|
Blue Star Invest SA | Chief Executive Officer | - |
CG Cube SA | Director/Board Member | - |
Le Bocholtz SA | Director/Board Member | - |
Mithra Pharmaceuticals CDMO SA
Mithra Pharmaceuticals CDMO SA Pharmaceuticals: MajorHealth Technology Part of Mithra Pharmaceuticals SA, Mithra Pharmaceuticals CDMO SA is a Belgian biotech company that focuses on transforming women's health through innovation. The private company is based in Liege, Belgium and has a global presence in over 100 countries with a staff count of approximately 300. Mithra CDMO is an integrated research, development, and manufacturing platform that takes products from proof of concept to market. The company's current research and development pipeline includes two products based on the novel natural estrogen, estetrol (e4), as well as three complex therapeutics. The company was founded in 2013, and the CEO is François Fornieri. | Director/Board Member | - |
Former positions of Guy Debruyne
Companies | Position | End |
---|---|---|
MITHRA PHARMACEUTICALS S.A. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MITHRA PHARMACEUTICALS S.A. | Health Technology |
Private companies | 4 |
---|---|
Le Bocholtz SA | |
Mithra Pharmaceuticals CDMO SA
Mithra Pharmaceuticals CDMO SA Pharmaceuticals: MajorHealth Technology Part of Mithra Pharmaceuticals SA, Mithra Pharmaceuticals CDMO SA is a Belgian biotech company that focuses on transforming women's health through innovation. The private company is based in Liege, Belgium and has a global presence in over 100 countries with a staff count of approximately 300. Mithra CDMO is an integrated research, development, and manufacturing platform that takes products from proof of concept to market. The company's current research and development pipeline includes two products based on the novel natural estrogen, estetrol (e4), as well as three complex therapeutics. The company was founded in 2013, and the CEO is François Fornieri. | Health Technology |
Blue Star Invest SA | |
CG Cube SA |
- Stock Market
- Insiders
- Guy Debruyne